Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00750399
Other study ID # FVF4519s
Secondary ID
Status Completed
Phase Phase 1
First received September 9, 2008
Last updated April 25, 2012
Start date October 2008
Est. completion date September 2011

Study information

Verified date April 2012
Source The New York Eye Cancer Center
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This is a Phase I clinical trial to test the safety and tolerability of intravitreal ranibizumab in the treatment of radiation retinopathy following plaque brachytherapy for patients with choroidal melanoma using the incidence and severity of events criteria.

The secondary objective is to assess the efficacy of intravitreal ranibizumab on regression of radiation retinopathy by ophthalmic examination, fundus photography, fluorescein angiography, and optical coherence tomography, as well as visual acuity.


Description:

Following plaque brachytherapy as treatment for choroidal melanoma, patients may develop radiation retinopathy. Radiation retinopathy is a progressive condition that leads to blindness in over 50% of cases within 5 years of treatment.

Vascular endothelial growth factor (VEGF) protein is believed to play a critical role in angiogenesis and radiation retinopathy. It is one of the key contributors to physiological or pathological conditions that can stimulate both the formation of new blood vessels and normal vessel incompetence. Ranibizumab is a recently approved vascular endothelial growth factor (VEGF) inhibitor shown to be effective in treating exudative macular degeneration. Ranibizumab binds to and inhibits vascular endothelial growth factor A (VEGF-A), which has been shown to cause neovascularization and leakage in models of ocular angiogenesis.

This is an open label, non-randomized active treatment, Phase I trial to assess the safety and tolerability of intravitreal ranibizumab and its ability to reduce radiation retinopathy and potentially limit vision loss associated with this disease.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date September 2011
Est. primary completion date September 2011
Accepts healthy volunteers No
Gender Both
Age group 21 Years and older
Eligibility Inclusion Criteria:

- Diagnosis of radiation retinopathy

- History of choroidal melanoma status post plaque brachytherapy

- Age > 21 years

- Ability to perform written consent and comply with study assessments for the full duration of the study

Exclusion Criteria:

- Pregnancy or lactation, pre-menopausal women not using contraception

- Participation in another simultaneous medical investigation or trial

- Patient with significantly compromised visual acuity in the study eye due to concomitant ocular conditions.

- Patients who have undergone intraocular surgery within last 60 days.

- Patients who have had intravitreal anti-VEGF treatment within 45 days.

- Patients who have had intravitreal triamcinolone acetonide within 4 months.

- Patients who have had laser within 60 days.

- Inability to obtain photographs to document CNV (including difficulty with venous access).

- Patient has a history of any medical condition which would preclude scheduled visits or completion of study.

- Aphakia or absence of the posterior capsule in the study eye. Previous violation of the posterior capsule in the study eye is also excluded unless as a result of yttrium aluminum garnet (YAG) posterior capsulotomy in association with posterior chamber lens implantation..

- History of glaucoma filtering surgery in the study eye.

- Concurrent use of more than two therapies for glaucoma.

- Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
Ranibizumab
intravitreal ranibizumab monthly for 4 months, and then every month thereafter until month 12.
ranibizumab
intravitreal ranibizumab 0.5 mg

Locations

Country Name City State
United States The New York Eye Cancer Center New York New York

Sponsors (2)

Lead Sponsor Collaborator
The New York Eye Cancer Center Genentech, Inc.

Country where clinical trial is conducted

United States, 

References & Publications (3)

Finger PT, Chin K. Anti-vascular endothelial growth factor bevacizumab (avastin) for radiation retinopathy. Arch Ophthalmol. 2007 Jun;125(6):751-6. — View Citation

Finger PT, Chin KJ. Intravitreous ranibizumab (lucentis) for radiation maculopathy. Arch Ophthalmol. 2010 Feb;128(2):249-52. doi: 10.1001/archophthalmol.2009.376. — View Citation

Finger PT. Radiation retinopathy is treatable with anti-vascular endothelial growth factor bevacizumab (Avastin). Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):974-7. doi: 10.1016/j.ijrobp.2007.11.045. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary To test the safety and tolerability of intravitreal ranibizumab in the treatment of radiation retinopathy associated with plaque brachytherapy for choroidal melanoma 12 months Yes
Secondary To assess the efficacy of intravitreal ranibizumab on treating radiation retinopathy following plaque brachytherapy for choroidal melanoma, and effect on visual acuity 12 months No
See also
  Status Clinical Trial Phase
Completed NCT00680225 - Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma Phase 3
Recruiting NCT03941379 - A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma
Completed NCT02875652 - Circulating Tumoral DNA in Choroidal Melanoma (ctDNA MU) N/A
Completed NCT00765921 - Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma Phase 1
Completed NCT00351728 - Combined PET/CT Imaging for the Early Detection of Ocular Melanoma Metastasis Compared to CT Scanning Alone N/A
Completed NCT01460810 - Safety and Efficacy of Silicone Oil Tamponade for Surgical Attenuation of Radiation Damage in Choroidal Melanoma N/A
Completed NCT01251978 - Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2) Phase 2
Completed NCT00344799 - Cytogenetic Study of Ocular Melanoma
Completed NCT01253759 - Long Term Results of Combined Transpupillary Thermotherapy (TTT) Indocyanine Green (ICG) Based Photodynamic Therapy (PDT) in Choroidal Melanoma Phase 4
Completed NCT03052127 - Study in Subjects With Small Primary Choroidal Melanoma Phase 1/Phase 2
Active, not recruiting NCT00111046 - Pain Relief - Tramadol Versus Ibuprofen Phase 1/Phase 2
Recruiting NCT06007690 - A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma Phase 3
Active, not recruiting NCT04417530 - Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma Phase 2
Terminated NCT05266430 - Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)